Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2011
10/27/2011WO2011131576A1 Tranylcypromine derivatives as inhibitors of histone demethylase lsd1 and/or lsd2
10/27/2011WO2011131407A1 Antibodies against human csf-1r and uses thereof
10/27/2011WO2011131314A1 Combination of drugs with protein-binding prodrugs
10/27/2011WO2011131135A1 Heteroaryl (alkyl) dithiocarbamate compounds, preparation methods and uses thereof
10/27/2011WO2011131103A1 Sphaelactone derivatives, their pharmaceutical compositions, preparation methods and uses
10/27/2011WO2011131102A1 Preparation method of lactone and use thereof
10/27/2011WO2011131034A1 4'-demethylepipodophyllotoxin derivative, preparation method and use thereof
10/27/2011WO2011131026A1 Furo[3, 2-g]chromene compounds and uses thereof
10/27/2011WO2011130921A1 Inhibitors of akt activity
10/27/2011WO2011130878A1 Tuberculosis vaccines including recombinant bcg strains overexpressing phop, and/or phop regulon protein(s)
10/27/2011WO2011109422A8 Compositions and methods for the treatment of cancer
10/27/2011WO2011088149A3 Methods for predicting response of triple-negative breast cancer to therapy
10/27/2011WO2011084451A3 Methods and compositions for liquidation of tumors
10/27/2011WO2011083998A3 Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient
10/27/2011WO2011081971A3 Fused thiophenes as dual inhibitors of egfr/vegfr and their use in the treatment of cancer
10/27/2011WO2011072205A3 Genetic markers indicative of a cancer patient response to trastuzumab (herceptin)
10/27/2011WO2011069045A3 Synthesis of syrbactin proteasome inhibitors
10/27/2011WO2011068894A3 Novel curcumin-antibody conjugates as anti-cancer agents
10/27/2011WO2011066503A3 Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
10/27/2011WO2011062420A3 Nanoparticles for tumor-targeting and processes for the preparation thereof
10/27/2011WO2011059262A3 Uses of apoptotic cell-targeting peptides, label substances and liposomes containing a therapeutic agent for preventing, treating or therapeutically diagnosing apoptosis-related diseases
10/27/2011WO2011038149A3 Methods of treating inflammation
10/27/2011WO2010133367A3 Novel solid materials of {[2s, 5r,8s,11s)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them
10/27/2011WO2010078421A8 Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
10/27/2011WO2002023190A8 Methods and products related to low molecular weight heparin
10/27/2011US20110265197 Signatures and PCDeterminants Associated with Prostate Cancer and Methods of Use Thereof
10/27/2011US20110264027 B ring reduced-d ring oxidized tetrapyrollic photosensitizers for photodynamic therapy and tumor imaging
10/27/2011US20110263920 Advanced methods and systems for treating cell proliferation disorders
10/27/2011US20110263721 Aryl di-substituted propenone compounds
10/27/2011US20110263720 Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same
10/27/2011US20110263713 Polymorphs
10/27/2011US20110263712 Process for the preparation of vorinostat
10/27/2011US20110263706 Method for enhancing the dna repair process, treating disorders associated with the dna repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering pruified quinic acid and/or carboxy alkyl ester
10/27/2011US20110263700 Antrocin containing pharmaceutical compositions for inhibiting cancer cells
10/27/2011US20110263694 Use of Xanthone Derivatives as a Medicament for Cancer
10/27/2011US20110263693 Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
10/27/2011US20110263688 Coferons and methods of making and using them
10/27/2011US20110263687 Rna molecules and uses thereof
10/27/2011US20110263685 Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy
10/27/2011US20110263684 Lipid Formulated Compositions and Methods for Inhibiting Expression of Serum Amyloid A Gene
10/27/2011US20110263680 Reduced size self-delivering rnai compounds
10/27/2011US20110263679 C12orf48 as a target gene for cancer therapy and diagnosis
10/27/2011US20110263672 Metabolites of Wortmannin Analogs and Methods of Using the Same
10/27/2011US20110263671 Novel salts of sunitinib
10/27/2011US20110263670 Novel polymorphs of sunitinib and processes for their preparation
10/27/2011US20110263669 Novel Pyrrolo [2,3-A] Carbazoles and Use Thereof as PIM Kinase Inhibitors
10/27/2011US20110263664 Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer
10/27/2011US20110263663 Synthesis of epothilones, intermediates thereto, analogues and uses thereof
10/27/2011US20110263659 Analogs of 1-Methylnicotinamide
10/27/2011US20110263656 Pirfenidone Treatment for Patients with Atypical Liver Function
10/27/2011US20110263653 Migrastatin analog compositions and uses thereof
10/27/2011US20110263650 Tubulysin D Analogues
10/27/2011US20110263649 Crystalline form of lenalidomide and a process for its preparation
10/27/2011US20110263647 Fluoroisoquinoline substituted thiazole compounds and methods of use
10/27/2011US20110263637 Up to six weeks dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod
10/27/2011US20110263636 3 x 3 x 3 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMOD
10/27/2011US20110263634 Lower dosage strength pharmaceutical compositions formulated with 2.5% imiquimod
10/27/2011US20110263633 Up to six weeks treatment regimen for treating actinic keratoses with pharmaceutical compositions formulated with 2.5% imiquimod
10/27/2011US20110263628 N-hydroxyamide derivatives and use thereof
10/27/2011US20110263622 Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors
10/27/2011US20110263616 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene maleate salt
10/27/2011US20110263607 Alpha helix mimetics in the treatment of cancer
10/27/2011US20110263604 Oxidase inhibitors and their use
10/27/2011US20110263602 Tetrasubstituted pyridazine hedgehog pathway antagonists
10/27/2011US20110263599 7-nonsubstituted indole mcl-1 inhibitors
10/27/2011US20110263598 Kinase inhibitors and method of treating cancer
10/27/2011US20110263597 Substituted pyridines and pyridazines with angiogenesis inhibiting activity
10/27/2011US20110263596 2-oxo-3-benzylbenzoxazol-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumours
10/27/2011US20110263595 Compounds and methods for kinase modulation, and indications therefor
10/27/2011US20110263594 Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors
10/27/2011US20110263593 NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS
10/27/2011US20110263587 Reversibly heat-gelable aqueous composition
10/27/2011US20110263581 Fused tricyclic compounds as serine-threonine protein kinase and parp modulators
10/27/2011US20110263575 Compounds Useful as Protein Kinase Inhibitors
10/27/2011US20110263566 7-Hydroxy-benzoimidazole-4-yl-methanone Derivatives and PBK Inhibitors Containing the Same
10/27/2011US20110263565 Compounds
10/27/2011US20110263563 Ansamycin Hydroquinone Compositions
10/27/2011US20110263562 Bicyclic compound
10/27/2011US20110263561 Novel pyrrolidone derivatives for use as MetAP-2 inhibitors
10/27/2011US20110263558 Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases
10/27/2011US20110263555 TGR5 Modulators and Methods of Use Thereof
10/27/2011US20110263548 Pyridone and pyridazone analogues as gpr119 modulators
10/27/2011US20110263547 C-19 steroids for specific therapeutic uses
10/27/2011US20110263546 Polyhydroxylated Bile Acids for Treatment of Biliary Disorders
10/27/2011US20110263541 Kinase inhibitors and their use as pharmaceutical agents
10/27/2011US20110263539 Ship 1 modulator compounds
10/27/2011US20110263533 Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
10/27/2011US20110263532 Halofuginone analogs for inhibition of trna synthetases and uses thereof
10/27/2011US20110263530 Aurora Kinase Modulators and Method of Use
10/27/2011US20110263526 Nitric Oxide Releasing Prodrugs of Therapeutic Agents
10/27/2011US20110263525 Drug composition cytotoxic for pancreatic cancer cells
10/27/2011US20110263524 Sns-595 and methods of using the same
10/27/2011US20110263523 Tet2 as a new diagnostic and pronostic marker in hematopoietic neoplasms
10/27/2011US20110263522 Antitumour compositions containing taxane derivatives
10/27/2011US20110263519 Regulators of the hedgehog pathway, compositions and uses related thereto
10/27/2011US20110263513 Pharmaceutical Being Used For Treating Cancer and Fibrosis Disease and the Composition and Uses Thereof
10/27/2011US20110263512 Conjugates for the treatment of mesothelioma
10/27/2011US20110263511 Tight junction protein modulators and uses thereof
10/27/2011US20110263504 Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
10/27/2011US20110263500 Curcumin Conjugates for Treating and Preventing Cancers
1 ... 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 ... 2211